Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
The California Medical Innovations Institute, Inc. · with Augusta University Medical Center · NCT05412069
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 155
- US sites recruiting
- 1
- Study start
- February 15, 2023
- Record last updated
- October 21, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The objective is to determine the length-tension properties of the anal sphincters using Fecobionics in normal subjects and FI patients during anal distension and during simulated evacuation. Fecobionics has the consistency and shape of normal stool and can record pressures, cross-sectional area, orientation and viscoelastic properties of the anorectum and can map the geometric profiles during evacuation, and thereby provides multi-dimensional measurements of pressures, deformability, and topographic changes. Fecobionics combines several existing tests to provide novel insight into anorectal function. The purpose for the development was to overcome the technological controversies and disagreement between various tests and unphysiological test conditions. The aim was to imitate defecation as much as possible to the natural process. Fecobionics was developed to simulate stool and to provide the driving pressure and resulting deformations of stool along with a measure of an objective anorectal angle during defecation in a single examination. Fecobionics makes it possible to describe objectively, without disturbing the defecation process, the opening characteristics and pressure signatures during initial entry into the relaxing anal canal.
The overall goal is to provide mechanistic understanding of defecation in health and defecatory disorders. It exceeds previous attempts to make artificial stool for evaluation of defecation (BET and FECOM) and integrates other technologies as well. It was designed to have a consistency and deformability of Type 4 (range type 3-5) on the Bristol stool form scale. The range from types 3-5 is found in 70% of normal subjects. A major novelty is that Fecobionics measures pressures in axial direction; i.e., in the flow direction.
Being studied: Fecobionics
Conditions: Normal Subjects; Fecal Incontinence
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subject must provide written informed consent;
- Willing and able to undergo required study tests, surveys, and procedures;
- Age > 18 years of age.
Exclusion Criteria
- Female who is pregnant;
- Prior anorectal surgery;
- Prior bowel resection;
- History of chronic constipation;
- In the opinion of the investigator, the subject is not a suitable candidate for the study.
Recruiting US locations
Augusta University Medical Center
Augusta, GA 30912
Site contact: Satish Rao, MD, PhD · 7067212238 · srao@augusta.edu
Study contacts (from the official record)
- Hans Gregersen, MD, PhD · 8582497400 · hag@giome.org
- Satish Rao, MD, PhD · 7067212238 · srao@augusta.edu
Similar studies in Georgia
All healthy volunteers studies in Georgia →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Influenza Human Challenge Model
Emory University
- Location
- Atlanta, GA + 1 other US site
- Eligibility basics
- Ages 18–49
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A/Texas Flu Challenge
Emory University
- Location
- Atlanta, GA + 1 other US site
- Eligibility basics
- Ages 18–49
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of BLB-201 RSV Vaccine in Infants and Children
Blue Lake Biotechnology Inc.
- Location
- Atlanta, GA + 13 other US sites
- Eligibility basics
- Ages 6 mo–5
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Decatur, GA + 49 other US sites
- Eligibility basics
- Ages 60+